Prenumeration
Curasight has received acceptance from the European Medicines Agency to begin its first clinical trial with uTREAT, a novel radiopharmaceutical therapy targeting cancer cells. The phase I trial will focus on patients with glioblastoma, the most common and deadliest form of brain cancer, with the first patient expected to be dosed before the end of 2025. The news means that Curasight is now in clinical development for both its diagnosis (uTRACE) and therapeutic (uTREAT) platforms. We turned to CEO Ulrich Krasilnikoff for a comment.
Read the full interview at biostock.se:
https://biostock.se/en/2025/08/curasight-to-enter-clinical-trials-with-utreat-in-brain-cancer/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/